The estimated Net Worth of Scott A Holmes is at least $6.35 Millón dollars as of 15 November 2018. Scott Holmes owns over 1,155 units of AMAG Pharmaceuticals stock worth over $4,073,900 and over the last 12 years Scott sold AMAG stock worth over $2,277,338.
Scott has made over 19 trades of the AMAG Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently Scott sold 1,155 units of AMAG stock worth $3,199 on 15 November 2018.
The largest trade Scott's ever made was selling 22,516 units of AMAG Pharmaceuticals stock on 3 June 2015 worth over $1,550,902. On average, Scott trades about 2,231 units every 70 days since 2012. As of 15 November 2018 Scott still owns at least 162,956 units of AMAG Pharmaceuticals stock.
You can see the complete history of Scott Holmes stock trades at the bottom of the page.
Scott's mailing address filed with the SEC is C/O AMAG PHARMACEUTICALS, INC., 100 HAYDEN AVENUE, LEXINGTON, MA, 02421.
Over the last 18 years, insiders at AMAG Pharmaceuticals have traded over $162,079,471 worth of AMAG Pharmaceuticals stock and bought 3,622,220 units worth $65,172,892 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Partners Gp, L.L.C.... y Capital Management Lp Camber. On average, AMAG Pharmaceuticals executives and independent directors trade stock every 42 days with the average trade being worth of $2,148,850. The most recent stock trade was executed by Capital Management Lp Camber on 1 October 2020, trading 4,390,000 units of AMAG stock currently worth $59,572,300.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
AMAG Pharmaceuticals executives and other stock owners filed with the SEC include: